glp-1 agonists for obesity Mechanisms of Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Resmetirom and GLP-1 agonists for

The GLP-1 receptor agonist market is growing rapidly, supported by rising obesity and diabetes prevalence, strong clinical outcomes, and increasing patient awareness

Heart J

Budget Constraints The Problem: Simply cant afford $1,000+/month long-term Need medication for 12-18+ months for full results $12,828+/year exceeds weight loss budget Other financial priorities compete The Solution: Affordable alternatives make long-term treatment financially sustainable

10.1210/clinem/dgae298 J Clin Endocrinol Metab

This finding could have significant implications because it suggests a higher risk of aspiration of 3.5 (95% CI 1.26 to 9.65) during anesthesia in patients taking Semaglutide compared to the control group

Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al